» Articles » PMID: 30102477

Psychiatric Morbidity and Quality of Life in Children and Adolescents with Cystic Fibrosis

Overview
Journal Turk J Pediatr
Specialty Pediatrics
Date 2018 Aug 14
PMID 30102477
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Şenses-Dinç G, Özçelik U, Çak T, Doğru-Ersöz D, Çöp E, Yalçın E, Çengel-Kültür E, Pekcan S, Kiper N, Ünal F. Psychiatric morbidity and quality of life in children and adolescents with cystic fibrosis. Turk J Pediatr 2018; 60: 32-40. The aim of this study was to investigate psychiatric disorders, depression and anxiety levels, and quality of life in children and adolescents with cystic fibrosis (CF), and to compare them with those of children with non-cystic fibrosis (non-CF) bronchiectasis and healthy controls. A total of 103 children and adolescents aged 7-16 years (35 CF, 28 non-CF bronchiectasis, 40 healthy) were evaluated using The Schedule for Affective Disorders and Schizophrenia for School Aged Children (K-SADS), The Child Depression Inventory (CDI), The State-Trait Anxiety Inventories for Children (STAI-C) and the Pediatric Quality of Life Inventory (PedsQL)-C. The three groups were not statistically different with respect to age, sex, and familial sociodemographic variables. 80% of the children and adolescents in the CF group were diagnosed with a psychiatric disorder, which was significantly more compared to those of the two other groups. The CF group had significantly greater rates of depressive and oppositional defiant disorder and the non-bronchiectasis group had a significantly greater rate of anxiety disorder than the control group. The depression and anxiety symptom levels were significantly greater and the quality of life levels significantly lower in both the CF and non-CF bronchiectasis groups than the healthy controls. In the CF group, the presence of any associated psychiatric disorder led to significantly lower total and psychosocial quality of life scores. In conclusion, CF is associated with poorer QOL in childhood. In order to improve quality of life in CF, the psychiatric conditions of children and adolescents should also be evaluated and their follow-up and treatment should involve a multidisciplinary team approach.

Citing Articles

Elexacaftor/Tezacaftor/Ivacaftor Treatment Accessibility and Mental Health: Reducing Anxiety in People With Cystic Fibrosis.

Uzunoglu B, Selcuk Balci M, Kalyoncu M, Karabulut S, Metin Cakar N, Yildiz C Pediatr Pulmonol. 2025; 60(3):e71037.

PMID: 40062574 PMC: 11892081. DOI: 10.1002/ppul.71037.


Impact of Anxiety, Depression, and Coping Strategies on Health-Related Quality of Life in Patients with Cystic Fibrosis.

Ceyhan B, Suner Z, Kocakaya D, Olgun Yildizeli S, Eryuksel E Thorac Res Pract. 2024; 25(4):149 - 157.

PMID: 38705998 PMC: 11363394. DOI: 10.5152/ThoracResPract.2024.23112.


Anxiety in Children with Low Vision Secondary to Refractive Errors.

Bekmez S, Eris D, Perente I Beyoglu Eye J. 2022; 5(3):194-198.

PMID: 35098087 PMC: 8784455. DOI: 10.14744/bej.2020.76993.


Anxiety in adolescents with severe asthma and response to treatment.

Licari A, Ciprandi R, Marseglia G, Ciprandi G Acta Biomed. 2021; 91(4):e2020186.

PMID: 33525309 PMC: 7927568. DOI: 10.23750/abm.v91i4.8806.